NCT06847555 Phase I-II Clinical Study of Taurine for External Use in the Prevention and Treatment of Acute Radiation Skin Injury
| NCT ID | NCT06847555 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Shandong Cancer Hospital and Institute |
| Condition | To Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-05-25 |
| Primary Completion | 2027-09-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2025-05-25 with a primary completion date of 2027-09-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute radiation skin injury is the most common side effect of radiation therapy in patients with chest tumors, which can be manifested as erythema, dry peeling, wet peeling, and severe ulcers. Even with current advanced radiotherapy techniques, such as intensity-modulated reverse radiation therapy (IMRT), about one-third of patients develop grade 2 or higher skin damage during radiotherapy. Radiation skin damage can cause discomfort to patients, thus affecting their daily life and reducing their quality of life. In severe cases, it can even reduce the efficacy due to prolonged treatment time. Therefore, prevention and treatment of acute radiation skin injury is a difficult problem to be solved urgently in clinical practice. Even with current advanced radiotherapy techniques, such as intensity-modulated reverse radiation therapy (IMRT), about one-third of patients develop grade 2 or higher skin damage during radiotherapy. Radiation skin damage can cause discomfort to patients, thus affecting their daily life and reducing their quality of life. In severe cases, it can even reduce the efficacy due to prolonged treatment time. Therefore, prevention and treatment of acute radiation skin injury is a difficult problem to be solved urgently in clinical practice. From previous studies, we found that taurine is an active substance that regulates normal physiological activities of the body and is widely distributed in various tissues and organs of the body. This substance has many advantages. Many previous studies have shown that taurine also has a wide range of biological functions such as anti-inflammatory, analgesic, maintaining osmotic pressure balance, improving visual function, regulating blood sugar, nerve conduction, endocrine activity, regulating lipid digestion and absorption, increasing cardiac contractility, improving immunity, enhancing cell membrane antioxidant capacity, protecting myocardial cells, etc. Considering the multiple medical values of taurine and its safety, we intend to conduct a phase I-II clinical study of taurine for external use in the prevention and treatment of acute radiation skin injury for radiation skin injury, with the study period from January 25,2024 to January 25,2027. The purpose is to evaluate the safety of taurine in the prevention and treatment of acute radiation skin injury in breast cancer patients after adjuvant radiotherapy. Possible benefits: Reduce the incidence and severity of radiation skin damage.
Eligibility Criteria
Inclusion Criteria: * Breast cancer patients scheduled for conventional fractionated adjuvant * radiotherapy. * 18 years or older * ECOG score 0-1 * No previous history of other neoplasms. * No previous chest radiotherapy. * Heart, lung function, liver function and kidney function were within normal range. * Voluntary informed consent. Exclusion Criteria: * Pregnant or lactating women, women in childbearing years who do not use effective contraception； * Patients with mental disease or nervous system disease, unable to clearly describe treatment response (such as cerebrovascular accident sequela); * Those who have serious heart, liver, kidney and other organ diseases or diabetes and are not expected to complete the treatment plan; * serious, uncontrolled diseases and infections; * Pregnant or lactating patients. * Allergic to taurine and any of its components. * Has participated in other clinical trials. * knot tissue disease * active hepatitis * Obvious diseases that the investigator considers should be excluded from this study
Frequently Asked Questions
Who can join the NCT06847555 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying To Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06847555 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06847555 currently recruiting?
Yes, NCT06847555 is actively recruiting participants. Visit ClinicalTrials.gov or contact Shandong Cancer Hospital and Institute to inquire about joining.
Where is the NCT06847555 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT06847555 clinical trial?
NCT06847555 is sponsored by Shandong Cancer Hospital and Institute. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.